Activation of caspase-dependent apoptosis by intracellular delivery of cytochrome c-based nanoparticles

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Morales Cruz, Moraima ^a   Figueroa, Cindy M ^a   González Robles, Tania ^a   Delgado, Yamixa ^a   Molina, Anna ^a   Méndez, Jessica ^a   Morales, Myraida ^a   Griebenow, Kai ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Drug delivery; Passive targeting; PLGA; Protein nanoparticles; Triggered release

Indexed keywords

C (PROGRAMMING LANGUAGE); CELL DEATH; CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; COVALENT BONDS; DISEASES; DRUG DELIVERY; LANTHANUM COMPOUNDS; NANOPARTICLES; PROTEINS; STEM CELLS; SULFUR COMPOUNDS;

ENHANCED PERMEABILITY AND RETENTION EFFECT; INTRACELLULAR DELIVERY; PASSIVE TARGETING; PLGA; POLY LACTIC-CO-GLYCOLIC ACID; PROGRAMMED CELL DEATHS; PROTEIN NANOPARTICLES; TRIGGERED RELEASE;

TARGETED DRUG DELIVERY;

3 (2 PYRIDYLDITHIO)PROPIONIC ACID N HYDROXYSUCCINIMIDE ESTER; 4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE; CYTOCHROME C; DISULFIDE; NANOPARTICLE; POLYGLACTIN; POLYMER; PROPIDIUM IODIDE; PROTEIN; SOLVENT; CASPASE 3; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL MODIFICATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PARTICLE SIZE; PRECIPITATION; PROTEIN SECRETION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM;

APOPTOSIS; CASPASE 3; CELL SURVIVAL; CYTOCHROMES C; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID;

EID: 84906839761     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-014-0033-9     Document Type: Article

References (35)

1. Danhier F, Feron O, Preat V. To exploit the tumor microenviroment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146. 10.1016/j.jconrel.2010.08.027.
2. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151. 10.1016/j.addr.2010.04.009.
3. Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev 2012, 64:505-519. 10.1124/pr.111.005363.
4. Morigi V, Tocchio A, Bellavite-Pellegrini C, Sakamoto JH, Arnone M, Tasciotti E. Nanotechnology in medicine: from inception to market domination. J Drug Deliv 2012, 2012:1-7. 10.1155/2012/389485.
5. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 1997, 94:9679-9683. 10.1073/pnas.94.18.9679.
6. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001, 13:332-337. 10.1016/S0955-0674(00)00216-7.
7. Santra S, Kaittanis C, Perez JM. Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Mol Pharm 2010, 7:1209-1222. 10.1021/mp100043h.
8. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 2008, 60:1439-1462. 10.1016/j.addr.2008.04.016.
9. Sola´ RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009, 98:1223-1245. 10.1002/jps.21504.
10. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res 2010, 27:544-575. 10.1007/s11095-009-0045-6.
11. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005, 2:29-42. 10.1517/17425247.2.1.29.
12. Slowing II, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. J Am Chem Soc 2007, 129:8845-8849. 10.1021/ja0719780.
13. Solaro R. Targeted delivery of protein drugs by nanocarriers. Materials 2010, 3:1928-1980. 10.3390/ma3031928.
14. Morales-Cruz M, Flores-Ferna´ndez GM, Morales-Cruz M, Orellano EA, Rodriguez-Martinez JA, Ruiz M, Griebenow K. Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres. Results Pharma Sci 2012, 2:79-85. 10.1016/j.rinphs.2012.11.001.
15. Me´ndez J, Morales-Cruz M, Delgado Y, Figueroa CM, Orellano EA, Morales M, Monteagudo A, Griebenow K. Delivery of chemically glycosylated cytochrome c immobilized in mesoporous silica nanoparticles induces apoptosis in hela cancer cells. Mol Pharm 2014, 11:102-111. 10.1021/mp400400j.
16. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003, 257:169-180. 10.1016/S0378-5173(03)00134-0.
17. Jahanshahi M, Babaei Z. Protein nanoparticle: a unique system as drug delivery vehicles. Afr J Biotechnol 2008, 7:4926-4934.
18. Zhao M, Biswas A, Hu B, Joo K, Wang P, Gu Z, Tang Y. Redox-responsive nanocapsules for intracellular protein delivery. Biomaterials 2011, 32:5223-5230. 10.1016/j.biomaterials.2011.03.060.
19. Shive M, Anderson J. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24. 10.1016/S0169-409X(97)00048-3.
20. Lu¨ JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in research and clinical applications of PLGA based nanotechnology. Expert Rev Mol Diagn 2009, 4:325-341. 10.1586/erm.09.15.
21. Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci 2013, 14:1629-1654. 10.3390/ijms14011629.
22. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63:131-135. 10.1016/j.addr.2010.03.011.
23. Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 2007, 3:103-110. 10.1016/j.nano.2006.12.002.
24. Griebenow K, Diaz-Laureano Y, Santos AM, Montañez-Clemente I, Rodriguez L, Vidal M, Barletta G. Improved enzyme activity and enantioselectivity in organic solvents by methyl-β-cyclodextrin. J Am Chem Soc 1999, 121:8157-8163. 10.1021/ja990515u.
25. Davies AM, Guillemette JG, Smith M, Greenwood C, Thurgood AG, Mauk AG, Moore GR. Redesign of the interior hydrophilic region of mitochondrial cytochrome c by site-directed mutagenesis. Biochemistry 1993, 32:5431-5435. 10.1021/bi00071a019.
26. Aachmann FL, Otzen DE, Larsen KL, Wimmer L. Structural background of cyclodextrin-protein interactions. Protein Eng 2003, 16:905-912. 10.1093/protein/gzg137.
27. Cooper A. Effect of cyclodextrins on the thermal stability of globular proteins. J Am Chem Soc 1992, 114:9208-9209. 10.1021/ja00049a074.
28. Me´ndez J, Monteagudo A, Griebenow K. Stimulus-responsive controlled release system by covalent immobilization of an enzyme into mesoporous silica nanoparticles. Bioconjug Chem 2012, 23:698-704. 10.1021/bc200301a.
29. Besaratinia A, Pfeifer GP. A review of mechanisms of acrylamide carcinogenicity. Carcinogenesis 2007, 28:519-528. 10.1093/carcin/bgm006.
30. Yu B, Zhang Y, Zheng W, Fan C, Chen T. Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles. Inorg Chem 2012, 51:8956-8963. 10.1021/ic301050v.
31. Choi SY, Jang SH, Park J, Jeong S, Park JH, Ock KS, Lee K, Yang SI, Joo SW, Ryu PD, Lee SY. Cellular uptake and cytotoxicity of positively charged chitosan gold nanoparticles in human lung adenocarcinoma cells. J Nanopart Res 2012, 14:1234. 10.1007/s11051-012-1234-5.
32. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226. 10.1096/fj.02-0088com.
33. Castellanos IJ, Griebenow K. Improved α-chymotrypsin stability upon encapsulation in PLGA microspheres by solvent replacement. Pharm Res 2003, 20:1873-1880. 10.1023/B:PHAM.0000003388.59659.fa.
34. Bratton SB, Salvesen GS. Regulation of the apaf-1-caspase-9 apoptosome. J Cell Sci 2010, 123:3209-3214. 10.1242/jcs.073643.
35. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000, 96:307-313.